B. 1. Rigau, V. Zouaoui, S. Mathieu-daudé, H. Darlix, A. Maran et al., French Brain Tumor DataBase: 5-Year Histological Results on 25???756 Cases, Brain Pathology, vol.8, issue.7, pp.633-677, 2004.
DOI : 10.1215/S1522851705000268

J. Schwartzbaum, J. Fisher, K. Aldape, and M. Wrensch, Epidemiology and molecular pathology of glioma, Nature Clinical Practice Neurology, vol.14, issue.9, pp.494-503, 2006.
DOI : 10.3171/foc.2005.19.5.6

M. Baron, L. Bauchet, and V. Bernier, Gliomes de grade II. EMC -Neurol, 2008.
DOI : 10.1016/s0246-0378(08)46100-6

T. Dolecek, J. Propp, N. Stroup, and C. Kruchko, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, 2005.

R. Soffietti, B. Baumert, L. Bello, V. Deimling, A. Duffau et al., Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, European Journal of Neurology, vol.27, issue.9, pp.1124-1157, 2010.
DOI : 10.1200/JCO.2008.20.5765

R. Stupp, M. Brada, M. Van-den-bent, J. Tonn, and G. Pentheroudakis, on behalf of the ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol ESMO, 2014.

S. Bracard, L. Taillandier, V. Antoine, S. Kremer, C. Taillandier et al., Imagerie c??r??brale des gliomes : diagnostic et suivi conventionnels, Journal de Radiologie, vol.87, issue.6, pp.779-91, 2006.
DOI : 10.1016/S0221-0363(06)74087-2

J. Pallud, L. Capelle, L. Taillandier, D. Fontaine, E. Mandonnet et al., Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro- Oncol, pp.176-82, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00349509

M. Xu, S. See, W. Ng, E. Arul, M. Back et al., Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors, Neurosurgery, vol.56, issue.5, pp.919-945, 2005.

K. Borbély, I. Nyáry, M. Tóth, K. Ericson, and B. Gulyás, Optimization of semiquantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas, J Neurol Sci Jul, vol.15246, issue.12, pp.85-94, 2006.

N. Galldiks, G. Stoffels, M. Ruge, M. Rapp, M. Sabel et al., Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma, Journal of Nuclear Medicine, vol.54, issue.12, pp.2046-54, 2013.
DOI : 10.2967/jnumed.113.123836

B. Fueger, J. Czernin, T. Cloughesy, D. Silverman, C. Geist et al., Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas, Journal of Nuclear Medicine, vol.51, issue.10, pp.1532-1540, 2010.
DOI : 10.2967/jnumed.110.078592

C. Nioche, M. Soret, E. Gontier, M. Lahutte, G. Dutertre et al., Evaluation of Quantitative Criteria for Glioma Grading With Static and Dynamic 18F-FDopa PET/CT, Clinical Nuclear Medicine, vol.38, issue.2, pp.81-88, 2013.
DOI : 10.1097/RLU.0b013e318279fd5a

S. Karunanithi, P. Sharma, A. Kumar, B. Khangembam, G. Bandopadhyaya et al., 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.34, issue.7, pp.1025-1060
DOI : 10.1097/RLU.0b013e3181becfe0

M. Otsuka, Y. Ichiya, Y. Kuwabara, S. Hosokawa, M. Sasaki et al., Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms, Journal of the Neurological Sciences, vol.136, issue.1-2, pp.169-73, 1996.
DOI : 10.1016/0022-510X(95)00316-T

R. Yee, D. Cheng, S. Huang, M. Namavari, N. Satyamurthy et al., Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-??-hydrazino-??-methyl-??-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, ??-(methylamino)isobutyric acid; MPTP, 1-methyl-1,2,3,6-tetrahydropyridine; PD, Parkinson???s disease; PET, positron emission tomography; and PLP, pyridoxal phosphate., Biochemical Pharmacology, vol.62, issue.10, pp.1409-1424, 2001.
DOI : 10.1016/S0006-2952(01)00787-0

C. Plathow and W. Weber, Tumor Cell Metabolism Imaging, Journal of Nuclear Medicine, vol.49, issue.Suppl_2, pp.43-63, 2008.
DOI : 10.2967/jnumed.107.045930

URL : http://jnm.snmjournals.org/content/49/Suppl_2/43S.full.pdf

R. Bergmann, J. Pietzsch, F. Fuechtner, B. Pawelke, B. Beuthien-baumann et al., 3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro, J Nucl Med Off Publ Soc Nucl Med, vol.45, issue.12, pp.2116-2138, 2004.

K. Kobayashi, A. Ohnishi, J. Promsuk, S. Shimizu, Y. Kanai et al., Enhanced Tumor Growth Elicited by L-Type Amino Acid Transporter 1 in Human Malignant Glioma Cells, Neurosurgery, vol.275, issue.2, pp.493-503, 2008.
DOI : 10.1074/jbc.275.7.5059

W. Heiss, K. Wienhard, R. Wagner, H. Lanfermann, A. Thiel et al., F-Dopa as an amino acid tracer to detect brain tumors, J Nucl, 1996.

W. Chen, D. Silverman, S. Delaloye, J. Czernin, N. Kamdar et al., 18F- FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.6, pp.904-915, 2006.

M. Tripathi, R. Sharma, D. Souza, M. Jaimini, A. Panwar et al., Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas, Clinical Nuclear Medicine, vol.34, issue.12, pp.878-83, 2009.
DOI : 10.1097/RLU.0b013e3181becfe0

C. Ledezma, W. Chen, V. Sai, B. Freitas, T. Cloughesy et al., 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience, European Journal of Radiology, vol.71, issue.2, pp.242-250, 2009.
DOI : 10.1016/j.ejrad.2008.04.018

C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S. Huang, 18F-FDOPA kinetics in brain tumors J Nucl Med Off Publ Soc Nucl Med, 96 28. afssaps. RAPPORT PUBLIC D'EVALUATION SCIENTIFIQUE discussion scientifique IASOdopa, Solution injectable FDOPA-(18F) (6-fluoro-(18F)-L-3, pp.1651-614, 2007.

F. Walter, T. Cloughesy, M. Walter, A. Lai, P. Nghiemphu et al., Impact of 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective, Journal of Nuclear Medicine, vol.53, issue.3, pp.393-401, 2012.
DOI : 10.2967/jnumed.111.095711

D. Figarella-branger, F. Labrousse, and K. Mohktari, R??f??rentiel gliomes diffus de l???adulte de grade OMS II,??III et IV??: anatomie pathologique et biologie, Annales de Pathologie, vol.32, issue.5, 2012.
DOI : 10.1016/j.annpat.2012.09.228

W. Chen and D. Silverman, Advances in Evaluation of Primary Brain Tumors, Seminars in Nuclear Medicine, vol.38, issue.4, pp.240-50, 2008.
DOI : 10.1053/j.semnuclmed.2008.02.005

C. Watling, D. Lee, D. Macdonald, and J. Cairncross, Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma., Journal of Clinical Oncology, vol.12, issue.9, pp.1886-1895, 1994.
DOI : 10.1200/JCO.1994.12.9.1886

M. Bondy, M. Scheurer, B. Malmer, J. Barnholtz-sloan, F. Davis et al., Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium, Cancer, vol.16, issue.2-3, pp.1953-68, 2008.
DOI : 10.1212/01.WNL.0000129533.26544.BF

E. Chang, A. Clark, R. Jensen, M. Bernstein, A. Guha et al., Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System, Journal of Neurosurgery, vol.16, issue.2, pp.203-213, 2009.
DOI : 10.1016/0360-3016(90)90397-3

P. Mckeever, D. Ross, M. Strawderman, J. Brunberg, H. Greenberg et al., A Comparison of the Predictive Power for Survival in Gliomas Provided by MIB-1, Bromodeoxyuridine and Proliferating Cell Nuclear Antigen with Histopathologic and Clinical Parameters, Journal of Neuropathology and Experimental Neurology, vol.56, issue.7, pp.798-805, 1997.
DOI : 10.1097/00005072-199756070-00006

H. Wakimoto, M. Aoyagi, T. Nakayama, G. Nagashima, S. Yamamoto et al., Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer, pp.373-80, 1996.

L. Bauchet, H. Mathieu-daude, P. Fabbro-peray, D. Henin, F. Labrousse et al., Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004, Neuro-Oncology, vol.71, issue.9311, pp.725-760, 2004.
DOI : 10.1016/S0140-6736(02)08091-1

W. Pope, J. Sayre, A. Perlina, J. Villablanca, P. Mischel et al., MR imaging correlates of survival in patients with high-grade gliomas, AJNR Am J Neuroradiol, 2005.

D. Fontaine and P. Paquis, Glioblastomes??: facteurs pronostiques cliniques, radiologiques et biologiques, Neurochirurgie, vol.56, issue.6, pp.467-76, 2010.
DOI : 10.1016/j.neuchi.2010.07.008

F. Ducray, A. Idbaih, X. Wang, C. Cheneau, M. Labussiere et al., Predictive and prognostic factors for gliomas, Expert Review of Anticancer Therapy, vol.130, issue.5, pp.781-790, 2011.
DOI : 10.1016/j.ccr.2006.11.021

R. Mclendon, A. Friedman, D. Bigner, V. Meir, E. Brat et al., Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, vol.123, issue.7216, pp.1061-1069, 2008.
DOI : 10.2174/187152008784220276

M. Esteller and J. Herman, Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer, Oncogene, vol.20, issue.1, pp.1-8, 2004.
DOI : 10.1002/mc.10094

R. Stupp, W. Mason, M. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005.
DOI : 10.1056/NEJMoa043330

D. Barone, T. Lawrie, and M. Hart, Image guided surgery for the resection of brain tumours, Cochrane Database of Systematic Reviews, vol.115, issue.2, p.9685, 2014.
DOI : 10.3171/2011.3.JNS101333

H. Duffau, Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity, The Lancet Neurology, vol.4, issue.8, pp.476-86, 2005.
DOI : 10.1016/S1474-4422(05)70140-X

P. Wen, D. Macdonald, D. Reardon, T. Cloughesy, A. Sorensen et al., Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-72, 2010.
DOI : 10.1200/JCO.2009.26.3541

P. Murphy, L. Viviers, C. Abson, I. Rowland, M. Brada et al., Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy, British Journal of Cancer, vol.17, issue.4
DOI : 10.1200/JCO.1999.17.9.2762

C. Burkhard, D. Patre, P. Schüler, D. Schüler, G. Ya?argil et al., A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma, Journal of Neurosurgery, vol.56, issue.6, pp.1170-1174, 2003.
DOI : 10.1177/088307389400900317

J. Pallud, L. Taillandier, L. Capelle, D. Fontaine, M. Peyre et al., Quantitative Morphological Magnetic Resonance Imaging Follow-up of Low-Grade Glioma, Neurosurgery, vol.29, issue.1, pp.729-769, 2012.
DOI : 10.1109/TMI.2009.2026413

L. Capelle, D. Fontaine, E. Mandonnet, L. Taillandier, J. Golmard et al., Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases, Journal of Neurosurgery, vol.19, issue.4, 2013.
DOI : 10.1016/S1474-4422(03)00434-4

H. Duffau and E. Mandonnet, The " onco-functional balance " in surgery for diffuse lowgrade glioma: integrating the extent of resection with quality of life, Acta Neurochir

D. Afra, O. De-witte, B. Hassel, M. Schraub, S. Hoang-xuan et al., Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, Feb Lancet, vol.28155366, issue.69490, pp.951-958, 2005.

M. Bent, T. Snijders, and J. Bromberg, Current treatment of low grade gliomas. Memo -Mag Eur Med Oncol, pp.223-230, 2012.

C. Levin and E. Hoffman, Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution, Phys Med Biol, 1999.

A. Varrone, S. Asenbaum, V. Borght, T. Booij, J. Nobili et al., EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.12, pp.2103-2113, 2009.
DOI : 10.1212/WNL.57.11.2083

A. Becherer, G. Karanikas, M. Szab, G. Zettinig, S. Asenbaum et al., Brain tumour imaging with PET: a comparison between

T. Singhal, T. Narayanan, M. Jacobs, C. Bal, and J. Mantil, 11C-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with 18F-FDG PET and Contrast Enhancement on MRI, Journal of Nuclear Medicine, vol.53, issue.11, pp.1709-1724, 2012.
DOI : 10.2967/jnumed.111.102533

V. Borght, T. Asenbaum, S. Bartenstein, P. Halldin, C. Kapucu et al., EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.11, pp.1374-80, 2006.
DOI : 10.1007/s00259-006-0206-3

R. Wahl, H. Jacene, Y. Kasamon, and M. Lodge, From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, Journal of Nuclear Medicine, vol.50, issue.Suppl_1, pp.122-150, 2009.
DOI : 10.2967/jnumed.108.057307

R. Harris, T. Cloughesy, W. Pope, P. Nghiemphu, A. Lai et al., 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab, Neuro-Oncology, vol.62, issue.10, pp.1079-89, 2012.
DOI : 10.1016/S0006-2952(01)00787-0

K. Herrmann, J. Czernin, T. Cloughesy, A. Lai, K. Pomykala et al., Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients, Neuro-Oncology, vol.40, issue.18, pp.603-612, 2014.
DOI : 10.1007/s00259-013-2384-0

Y. Okita, M. Kinoshita, T. Goto, N. Kagawa, H. Kishima et al., 11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: A stereotactic image-histology comparison, NeuroImage, vol.49, issue.4, pp.2977-82, 2010.
DOI : 10.1016/j.neuroimage.2009.11.024

T. Sasajima, T. Miyagawa, T. Oku, J. Gelovani, R. Finn et al., Proliferationdependent changes in amino acid transport and glucose metabolism in glioma cell lines Available from, Eur J Nucl Med Mol Imaging [Internet], vol.31, issue.9, pp.259-263, 2004.

D. In, improve survival: the standard treatment is surgery In cases of incomplete resection or aggressive type of tumor, chemotherapy and radiotherapy are options. Post-operative radiotherapy is discussed depending on prognostic factors (17) Chemotherapy has less side effects regarding cognitive toxicity and neuroplasticity than radiotherapy (18) The aim is to prolong survival while preserving quality of life and to control tumoral mass-related symptoms. On the contrary, the treatment of HGG is based on primary surgery as large as feasible and on adjuvant radiochemotherapy or continuous chemotherapy (18) So it is of crucial importance to detect malignant transformation and optimal time for commencing adjuvant treatments

V. Rigau, S. Zouaoui, H. Mathieu-daudé, A. Darlix, A. Maran et al., French Brain Tumor DataBase: 5-Year Histological Results on 25???756 Cases, Brain Pathology, vol.8, issue.7, pp.633-677, 2004.
DOI : 10.1215/S1522851705000268

J. Schwartzbaum, J. Fisher, K. Aldape, and M. Wrensch, Epidemiology and molecular pathology of glioma, Nature Clinical Practice Neurology, vol.14, issue.9, pp.494-503, 2006.
DOI : 10.3171/foc.2005.19.5.6

D. Louis, H. Ohgaki, O. Wiestler, W. Cavenee, A. Jouvet et al., The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, vol.64, issue.2, pp.97-109, 2007.
DOI : 10.1093/jnen/60.9.863

L. Capelle, D. Fontaine, E. Mandonnet, L. Taillandier, J. Golmard et al., Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases, Journal of Neurosurgery, vol.19, issue.4, 2013.
DOI : 10.1016/S1474-4422(03)00434-4

R. Soffietti, B. Baumert, L. Bello, V. Deimling, A. Duffau et al., Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, European Journal of Neurology, vol.27, issue.9, pp.1124-1157, 2010.
DOI : 10.1200/JCO.2008.20.5765

L. Bauchet, H. Mathieu-daude, P. Fabbro-peray, V. Rigau, M. Fabbro et al., Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004, Neuro-Oncology, vol.71, issue.9311, pp.725-760, 2004.
DOI : 10.1016/S0140-6736(02)08091-1

F. Ducray, A. Idbaih, X. Wang, C. Cheneau, M. Labussiere et al., Predictive and prognostic factors for gliomas, Expert Review of Anticancer Therapy, vol.130, issue.5, pp.781-790, 2011.
DOI : 10.1016/j.ccr.2006.11.021

G. Cairncross, M. Wang, E. Shaw, R. Jenkins, D. Brachman et al., Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402, Journal of Clinical Oncology, vol.31, issue.3, pp.337-380, 2013.
DOI : 10.1200/JCO.2012.43.2674

P. Wen, D. Macdonald, D. Reardon, T. Cloughesy, A. Sorensen et al., Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-72, 2010.
DOI : 10.1200/JCO.2009.26.3541

T. Hirai, R. Murakami, H. Nakamura, M. Kitajima, H. Fukuoka et al., Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study, American Journal of Neuroradiology, vol.239, issue.3, pp.1505-1515, 2008.
DOI : 10.1148/radiol.2393042031

W. Heiss, K. Wienhard, R. Wagner, H. Lanfermann, A. Thiel et al., F-Dopa as an amino acid tracer to detect brain tumors, J Nucl, 1996.

C. Plathow and W. Weber, Tumor Cell Metabolism Imaging, Journal of Nuclear Medicine, vol.49, issue.Suppl_2, pp.43-63, 2008.
DOI : 10.2967/jnumed.107.045930

URL : http://jnm.snmjournals.org/content/49/Suppl_2/43S.full.pdf

T. Sasajima, T. Miyagawa, T. Oku, J. Gelovani, R. Finn et al., Proliferationdependent changes in amino acid transport and glucose metabolism in glioma cell lines

R. Yee, D. Cheng, S. Huang, M. Namavari, N. Satyamurthy et al., Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-??-hydrazino-??-methyl-??-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, ??-(methylamino)isobutyric acid; MPTP, 1-methyl-1,2,3,6-tetrahydropyridine; PD, Parkinson???s disease; PET, positron emission tomography; and PLP, pyridoxal phosphate., Biochemical Pharmacology, vol.62, issue.10, pp.1409-1424, 2001.
DOI : 10.1016/S0006-2952(01)00787-0

W. Chen, D. Silverman, S. Delaloye, J. Czernin, N. Kamdar et al., 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.6, pp.904-915, 2006.

B. Fueger, J. Czernin, T. Cloughesy, D. Silverman, C. Geist et al., Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas, Journal of Nuclear Medicine, vol.51, issue.10, pp.1532-1540, 2010.
DOI : 10.2967/jnumed.110.078592

M. Van-den-bent, D. Afra, O. De-witte, B. Hassel, M. Schraub et al., Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, The Lancet, vol.366, issue.9490, pp.985-90, 2005.
DOI : 10.1016/S0140-6736(05)67070-5

R. Stupp, W. Mason, M. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005.
DOI : 10.1056/NEJMoa043330

J. Pallud, L. Capelle, L. Taillandier, D. Fontaine, E. Mandonnet et al., Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro-Oncol, pp.176-82, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00349509

C. Watling, D. Lee, D. Macdonald, and J. Cairncross, Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma., Journal of Clinical Oncology, vol.12, issue.9, pp.1886-1895, 1994.
DOI : 10.1200/JCO.1994.12.9.1886

C. Nioche, M. Soret, E. Gontier, M. Lahutte, G. Dutertre et al., Evaluation of Quantitative Criteria for Glioma Grading With Static and Dynamic 18F-FDopa PET/CT, Clinical Nuclear Medicine, vol.38, issue.2, pp.81-88, 2013.
DOI : 10.1097/RLU.0b013e318279fd5a

C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S. Huang, 18F-FDOPA Kinetics in Brain Tumors, Journal of Nuclear Medicine, vol.48, issue.10, pp.1651-61, 2007.
DOI : 10.2967/jnumed.106.039321

R. Harris, T. Cloughesy, W. Pope, P. Nghiemphu, A. Lai et al., 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab, Neuro-Oncology, vol.62, issue.10, 2012.
DOI : 10.1016/S0006-2952(01)00787-0

Y. Okita, M. Kinoshita, T. Goto, N. Kagawa, H. Kishima et al., 11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: A stereotactic image-histology comparison, NeuroImage, vol.49, issue.4, pp.2977-82, 2010.
DOI : 10.1016/j.neuroimage.2009.11.024

S. Srinivas, T. Dhurairaj, S. Basu, G. Bural, S. Surti et al., A recovery coefficient method for partial volume correction of PET images, Annals of Nuclear Medicine, vol.45, issue.4, 2009.
DOI : 10.1148/radiology.188.2.8327702